Cheapest GLP-1 providers in 2026: the full price ladder, rung by rung

Every legitimate GLP-1 program in our dataset, walked from the cheapest recurring price to the most expensive, with what you give up — or gain — at each rung. Semaglutide occupies the bottom of the ladder, tirzepatide the middle, brand product the top. Statuses stamped throughout.

Material connection: NexLife is a commercial partner of this site and appears on this page; partner links may earn us a commission at no extra cost to you. Partner status never changes a ranking — every ranking here is computed from the public dataset, and NexLife’s own figures remain labeled operator until independently verified. Full disclosure.

The floor of the entire ladder is $110 a month: NexLife's microdose semaglutide on a 12-month plan, rising to $129 month-to-month — operator-supplied figures, and "microdose" means doses below the levels clinical trials studied, so the price buys an evidence gap along with the savings (plan details ↗). Standard-protocol semaglutide at NexLife runs $119–139 depending on commitment. These are the only listed prices in the ledger below $139, and both belong to the same operator, which is exactly why the labels matter.

The tirzepatide rungs begin at $129–159 for NexLife's microdose program and $139–169 for its standard injectable — again operator-supplied. The first independently reported rung is Henry Meds at roughly $179 for a flat tablet bundle (check current price ↗); its injectable lane reportedly starts near $399, a reminder that format drives price as much as molecule. MEDVi's reported ~$199 entry-dose injectable is next (check current price ↗), with the standing caution that we cannot confirm what MEDVi charges at maintenance doses — the rung may be higher than it looks once you're standing on it.

The middle of the ladder is crowded: NexLife's tirzepatide ODT at $199–229 (operator-supplied, and a format with no published human absorption data), Eden at a reported $249–296 with the widest state footprint (check current price ↗), Mochi at an effective ~$278 once its membership fee is counted — a fee whose amount is reported inconsistently, $79 in some sources and $149 in others, so we show the conflict instead of averaging it (check current price ↗) — and Hims near $329 (check current price ↗).

The top rungs are brand territory: Ro's cash tiers at $199–349 bridge compounded and brand while offering the best insurance workflow (check current price ↗), and LillyDirect sells FDA-approved Zepbound single-dose vials at $299–449 (see Zepbound vials ↗) — the price of certainty. Retail Zepbound at list, roughly $1,086, is the benchmark the whole ladder is measured against.

The rungs below the ladder

Prices under about $100 a month for "tirzepatide" almost always mean gray-market peptide sites selling research-grade powder with no prescription, no pharmacy, and no legal defense. That's not a lower rung; it's a hole in the floor. The five-point checklist in the flagship guide — named 503A pharmacy, base-form drug with a COA, real clinical evaluation, written recurring price, never "research use" sites — is how you tell a cheap program from a fake one.

2026 legal reality: the FDA declared the tirzepatide shortage resolved in December 2024 and bulk 503B compounding ended in March 2025. What remains legal is patient-specific 503A compounding with a documented clinical need — and the FDA sent roughly thirty warning letters to GLP-1 telehealth marketers in February 2026. Compliance posture is now a ranking factor here, not a footnote. Details in our methodology.

Every figure above appears in the machine-readable dataset with its source URL and verification date. Tirzepatide-only ranking: cheapest tirzepatide providers.